Note: results can be filtered by year and/or keyword. To filter on year, select the appropriate year from the drop down menu. To filter on keyword, enter relevant term into open box, select appropriate keyword, and click "filter".
Statements, Speeches, Letters
Open letter to the European Commission on the follow-up of the June 2016 EU Council Conclusions on “Strengthening the Balance in the Pharmaceutical Systems in the EU and its Member States”
On 17 June, 2016, all 28 European Union (EU) Health Ministers agreed on Council Conclusions to address the imbalances in the pharmaceutical systems in the EU and its Member States. In these Conclusions, the Ministers invited the European Commission to undertake a critical review of the impact of current intellectual property (IP) related incentives on biomedical innovation.
Last updated 14 September 2016
Mr. Gregg Alton Executive Vice President Corporate and Medical Affairs Gilead Sciences Inc. 333 Lakeside Dr Foster City, CA 94404 Re: Gilead Sciences attempts to remove generic sofosbuvir from Ukraine
Last updated 6 September 2016
30 May 2016 To, China, India, Australia, New Zealand, Myanmar, Lao, Cambodia, Indonesia, Thailand, Vietnam, Malaysia, Brunei, Philippines, Singapore, Japan, South Korea Intellectual Property and Least Developed Countries (LDCs) Protect Transition Period for LDCs
Rohit Malpani, director of policy and analysis at Doctors Without Borders/Médecins Sans Frontières’ (MSF) Access Campaign, delivered the following remarks at Meeting the Challenge of Antimicrobial Resistance, an event hosted by the United Nations’ Every Woman Every Child movement.
MSF welcomes WHO’s Global Health Sector Strategy on HIV and urges Member States to rapidly adopt and implement WHO’s HIV guidelines, particularly the recommendation to provide antiretroviral therapy to all people living with HIV upon diagnosis. Evidence shows ‘treat all’ - also known as test and treat - policies can decrease the risk of developing AIDS by 57%, reduce the risk of sexual transmission by 96%, and give most people living with HIV a life expectancy comparable to HIV-negative people.
At the 68th WHA, resolution 68.6 – co-sponsored by 18 countries – was adopted, turning the pleas of governments that have for years appealed to the global community for help to combat high vaccine prices into action. MSF acknowledges the GVAP Secretariat report and appreciates the initial steps taken to report upon progress towards implementing resolution 68.6. However, it is concerning that the first report back does not include any concrete steps on actions being taken to lower the price of vaccines.
WHO 69th World Health Assembly: Agenda item 16.4 – Addressing the global shortages of medicines, and the safety and accessibility of children’s medication
Sustained availability of quality-assured medicines is a global health priority. Multiple barriers -- from supply chain difficulties to manufacturing problems -- contribute to the failure of meeting that priority, resulting in stock outs of medicines that people often experience.
WHO 69th World Health Assembly: Agenda item 16.2 – the Consultative Expert Working Group on Research and Development: Financing and Coordination
As Member States continue negotiating the CEWG, it’s important to note that the warnings and call to action underlined in the report are more relevant now than ever.
MSF witnesses antibiotic resistance in our programmes, including child nutrition centres in Niger, burns units in Iraq and adult trauma centres in Jordan and documented very resistant bacteria in our projects. In recent years we have used last-line antibiotics for multi-drug resistant gram-negative infections.
MSF at WHO's Open-Ended Meeting on CEWG - Agenda Item 5(j-k): Discussion on Future Financing of health R&D
At the 68th World Health Assembly, resolution 66.22 requested the Director-General to convene an open-ended meeting of Member States prior to the 69th World Health Assembly, in order to assess progress and continue discussions of the Consultative Expert Working Group (CEWG) on the remaining issues in relation to monitoring, coordination and financing for health research and development. The three-day meeting takes place from 2nd to 4th May 2016 at WHO Headquarters.